Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.

about

Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma.

P2860

Q37688207-EE62FBA9-FE98-4BBB-A339-A235D380BCA4 Q41195862-B0DD0402-A3F0-4393-A8A5-96A5E5471DE6 Q43376041-E6CD44E1-E2A1-4AB4-8D7E-A850DC91DDE1

P2860

Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.

Item

http://www.wikidata.org/entity/Q40147550

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cilengitide restrains the oste ...... ivity of myeloma plasma cells.

@en

type

Item

label

Cilengitide restrains the oste ...... ivity of myeloma plasma cells.

@en

prefLabel

Cilengitide restrains the oste ...... ivity of myeloma plasma cells.

@en

P1476

Cilengitide restrains the oste ...... ivity of myeloma plasma cells.

@en

P2093

Claudia Felici

http://www.w3.org/2001/XMLSchema#string

Leonardo Resta

http://www.w3.org/2001/XMLSchema#string

Roberta Rossi

http://www.w3.org/2001/XMLSchema#string

Stefania Stucci

http://www.w3.org/2001/XMLSchema#string

P2860

Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Lenalidomide in multiple myeloma: current experimental and clinical data.

Biology of osteoclast activation in cancer.

Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

Integrin signalling during tumour progression.

P304

59-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13922

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

173

http://www.w3.org/2001/XMLSchema#string

P50

Marco Tucci

Paola Cafforio

Francesco Silvestris

P577

2016-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289489488

http://www.w3.org/2001/XMLSchema#string

P698

26728969

http://www.w3.org/2001/XMLSchema#string

Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.

about

P2860

P2860

Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698